Endo Operations Ltd

2 of its medicines lose their last listed patent or exclusivity between January 1, 2026 and December 31, 2027.

June 16, 2026Supprelin LAhistrelin acetate
May 8, 2027Aveedtestosterone undecanoate

Dates are the patent and exclusivity end dates listed in the FDA's Orange Book, in its data up to October 9, 2026. Patents can be extended, challenged in court or settled, so a generic may come earlier, later or not at all. This is not legal or medical advice.

About the data·Privacy·Credits